Adona Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Adona Medical is pioneering a next-generation, minimally invasive solution for heart failure with its investigational Adona Interatrial Shunt system. The device's key differentiators are its post-implant adjustability, enabled by shape-memory nitinol and a proprietary induction catheter, and its integrated bi-atrial pressure monitoring sensors. The company has raised significant venture capital, completed enrollment in its first-in-human trial as of mid-2025, and is positioned to address a significant unmet need in the structural heart and advanced heart failure markets.

CardiovascularHeart FailureStructural Heart Disease

Technology Platform

A minimally invasive interatrial shunt system featuring a shape-memory nitinol shunt with post-implant adjustability, integrated bi-atrial pressure sensors, and a proprietary catheter-based induction system for non-contact lumen reduction.

Opportunities

The massive and growing global heart failure patient population, particularly those with advanced disease, represents a multi-billion dollar market with high unmet need.

Adona's unique combination of adjustable shunting and direct hemodynamic monitoring positions it to offer a more personalized and data-driven therapy than first-generation fixed shunts, potentially capturing significant market share and commanding a premium price.

Risk Factors

Key risks include clinical trial failure or serious safety events, unproven long-term reliability of the sensor and adjustment mechanism in humans, and regulatory hurdles.

The company also faces competition from other interatrial shunt developers and must establish clinical utility and secure favorable reimbursement for its advanced features.

Competitive Landscape

Adona competes in the emerging interatrial shunt therapy market. Direct competitors include Corvia Medical (fixed IASD device) and V-Wave (pressure-regulated shunt), which have first-mover advantage and some regulatory approvals. Other competitors include Edwards Lifesciences (FORMA spacer) and broader advanced heart failure device/drug companies. Adona's differentiation lies in its post-implant adjustability and integrated pressure monitoring.

More companies in Small Molecule Drugs →More companies in United States →